Jpa. Ioannidis et al., Recursive cumulative meta-analysis: A diagnostic for the evolution of total randomized evidence from group and individual patient data, J CLIN EPID, 52(4), 1999, pp. 281-291
Citations number
49
Categorie Soggetti
Envirnomentale Medicine & Public Health","Medical Research General Topics
Meta-analyses of randomized evidence may include published, unpublished, an
d updated data in an ongoing estimation process that continuously accommoda
tes more data. Synthesis may be performed either with group data or with me
ta-analysis of individual patient data (MIPD). Although MIPD with updated d
ata is considered the gold standard of evidence, there is a need for a care
ful study of the impact different sources of data have on a meta-analysis a
nd of the change in the treatment effect estimates over sequential informat
ion steps. Unpublished data and late-appearing data may be different from e
arly-appearing data. Updated information after the end of the main study fo
llow-up may be affected by cross-overs, missing information, and unblinding
. The estimated treatment effect may thus depend on the completeness and up
dating of the available evidence. To address these issues, we present recur
sive cumulative meta-analysis (RCM) as an extension of cumulative metaanaly
sis. Recursive cumulative meta-analysis is based on the principle of recalc
ulating the results of a cumulative meta-analysis with each new or updated
piece of information and focuses on the evolution of the treatment effect a
s a more complete and updated picture of the evidence becomes available. An
examination of the perturbations of the cumulative treatment effect over s
equential information steps may signal the presence of bias or heterogeneit
y in a meta-analysis. Recursive cumulative meta-analysis may suggest whethe
r then is a true underlying treatment effect to which the meta-analysis is
converging and how treatment effects are sequentially altered by new or mod
ified evidence. The method is illustrated with an example from the conduct
of an MIPD on acyclovir in human immunodeficiency virus infection. The rela
tive strengths and limitations of both meta analysis of group data and MIPD
are discussed through the RCM perspective. (C) 1999 Elsevier Science Inc.